Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting

Aldeyra Therapeutics, Inc.

(Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel anti-inflammatory data on its lead product candidate, NS2, has been accepted for a late-breaking poster presentation at the upcoming 2015 American Academy of Allergy Asthma & Immunology Annual Meeting, being held February 20-24, 2015 in Houston, Texas. Aldeyra will present the objectives, methods and results of studies evaluating a small molecule aldehyde trapping agent, NS2, found to provide benefit in murine models of inflammation. The abstract and timing of the presentation is provided below. The Small Molecule Aldehyde Trap NS2 Exhibits Potent Anti-Inflammatory Activity in Three Murine Models of Inflammation Poster: L11 General Poster Session: 5211 Date, Time: Tuesday, February 24, 2015 at 9:45am Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, "Acceptance of our data for a late-breaking poster presentation at AAAAI highlights the scientific and medical communities' deep interest in novel anti-inflammatory mechanisms. We are encouraged by the data and believe NS2 may represent a viable adjunct or alternative to steroids and other anti-inflammatory medications." NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping free aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate pathologic inflammation. As a product candidate, NS2 is currently being evaluated to address two underserved rare diseases, noninfectious anterior uveitis and Sjögren-Larsson Syndrome.